Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma 3Leukemia 3Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia × forodesine × Clear all
NCT00289549 2012-02-08

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

Phase 2 Completed
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00289562 2012-01-20

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

BioCryst Pharmaceuticals

Phase 1/2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡